2023
Isolation and Quarantine for Coronavirus Disease 2019 in the United States, 2020–2022
Oeltmann J, Vohra D, Matulewicz H, DeLuca N, Smith J, Couzens C, Lash R, Harvey B, Boyette M, Edwards A, Talboy P, Dubose O, Regan P, Loosier P, Caruso E, Katz D, Taylor M, Moonan P. Isolation and Quarantine for Coronavirus Disease 2019 in the United States, 2020–2022. Clinical Infectious Diseases 2023, 77: 212-219. PMID: 36947142, PMCID: PMC11094624, DOI: 10.1093/cid/ciad163.Peer-Reviewed Original ResearchConceptsCoronavirus disease 2019Case patientsDisease 2019Positive severe acute respiratory syndrome coronavirus 2 test resultAdult case patientsCase investigationCOVID-19Public health programsPublic health workforceHealth programsHealth workforceContact tracingPatientsHealth officialsMost adultsAdultsDaysImpact of contactRepresentative sampleTotalMore adultsPanel SurveyQuarantine
2021
Sensitive and Feasible Specimen Collection and Testing Strategies for Diagnosing Tuberculosis in Young Children
Song R, Click ES, McCarthy KD, Heilig CM, Mchembere W, Smith JP, Fajans M, Musau SK, Okeyo E, Okumu A, Orwa J, Gethi D, Odeny L, Lee SH, Perez-Velez CM, Wright CA, Cain KP. Sensitive and Feasible Specimen Collection and Testing Strategies for Diagnosing Tuberculosis in Young Children. JAMA Pediatrics 2021, 175: e206069. PMID: 33616611, PMCID: PMC7900937, DOI: 10.1001/jamapediatrics.2020.6069.Peer-Reviewed Original ResearchConceptsGastric aspiratesNPA samplesResource-limited settingsCurrent reference standardDiagnostic yieldTuberculosis diagnosisXpert MTB/RIFCross-sectional diagnostic studyReference standardNasopharyngeal aspirate samplesSymptoms of tuberculosisMycobacteria growth indicator tube (MGIT) cultureMTB/RIFIncremental diagnostic yieldPositive test resultsYoung childrenSpecimen typesInvasive specimenCervical lymphadenopathyMedian ageMycobacterium tuberculosis complexParenchymal abnormalitiesConsecutive seriesOutpatient settingAspirate samples
2020
The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events.
Smith JP, Gandhi NR, Shah NS, Mlisana K, Moodley P, Johnson BA, Allana S, Campbell A, Nelson KN, Master I, Brust JCM. The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 83: 47-55. PMID: 31809360, PMCID: PMC6903405, DOI: 10.1097/qai.0000000000002190.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisConcurrent antiretroviral therapyMDR-TB patientsMDR-TB treatmentLaboratory adverse eventsAdverse eventsHIV coinfectionAntiretroviral therapyHIV statusConcurrent treatmentCommon clinical adverse eventsCommon laboratory adverse eventsCo-infected participantsColor discrimination testingMDR-TB therapyAntiretroviral therapy initiationFrequent adverse eventsClinical adverse eventsProspective observational studyFavorable treatment outcomesColor discrimination lossesTherapy initiationConcurrent therapyCreatinine clearanceVision loss
2017
Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa
Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, Johnson BA, Master I, Mthiyane T, Lachman S, Larkan LM, Ning Y, Malik A, Smith JP, Gandhi NR. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa. Clinical Infectious Diseases 2017, 66: 1246-1253. PMID: 29293906, PMCID: PMC5888963, DOI: 10.1093/cid/cix1125.Peer-Reviewed Original ResearchConceptsCells/mm3Immunodeficiency virus coinfectionAntiretroviral therapyMDR tuberculosisCD4 countVirus coinfectionConcurrent treatmentTreatment outcomesHuman immunodeficiency virus (HIV) coinfectionUndetectable HIV viral loadConcurrent antiretroviral therapyMDR tuberculosis patientsHIV viral loadMultidrug-resistant tuberculosisStrong risk factorTuberculosis-HIVTuberculosis outcomesAdverse eventsTuberculosis patientsImproved survivalMedian agePrimary outcomeHIV statusViral loadCure rate
2013
Aspiring to Zero Tuberculosis Deaths among Southern Africa's Miners: Is There a Way Forward?
Dharmadhikari A, Smith J, Nardell E, Churchyard G, Keshavjee S. Aspiring to Zero Tuberculosis Deaths among Southern Africa's Miners: Is There a Way Forward? International Journal Of Social Determinants Of Health And Health Services 2013, 43: 651-664. PMID: 24397232, DOI: 10.2190/hs.43.4.d.Peer-Reviewed Original ResearchMeSH KeywordsAfrica, SouthernComorbidityDisease ProgressionEarly DiagnosisHIV InfectionsHousingHumansImmunocompromised HostLatent TuberculosisMaleMiningOccupational DiseasesOccupational Health ServicesSecondary PreventionSilicosisSocial ConditionsTuberculosisTuberculosis, Multidrug-ResistantWorkforceConceptsTuberculosis notification ratesNotification ratesDrug-resistant strainsSpread of tuberculosisHigh rateTuberculosis deathsActive tuberculosisHIV infectionSouth African minersImmediate treatmentTuberculosis diseaseConcurrent treatmentTuberculosis mortalityGeneral populationAppropriate managementTuberculosisSilica dustActive casesBiomedical interventionsDiseaseDeathAirborne diseasesInfectionPoor workingAfrican miners